This article is more than 5 years old. Information may no longer be current.

EyeGate reports $2.4 million net loss in first quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyeGate Pharmaceuticals reported a net loss of $2.4 million in the first quarter compared with a net loss of $11 million in the same quarter of 2015, according to a press release.

Research and development expenses were reported at $0.9 million in the first quarter compared with $0.3 million in the same quarter of 2015. The increase was attributed to the resumption of a phase 3 clinical trial for the treatment of anterior uveitis, a phase 1/2 macular edema trial, and research and development expenses related to Jade’s CMHA-S-based product pipeline.

General and administrative expenses were reported at $1.5 million in the first quarter compared with $0.8 million in the same quarter of 2015.